.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Argus Health
US Army
Fish and Richardson
Covington
Queensland Health
Moodys
Farmers Insurance
Cerilliant

Generated: December 17, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,900,566

« Back to Dashboard

Which drugs does patent 8,900,566 protect, and when does it expire?


Patent 8,900,566 protects DAKLINZA and is included in one NDA.

This patent has forty-seven patent family members in thirty-one countries.

Summary for Patent: 8,900,566

Title:Hepatitis C virus inhibitors
Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
Inventor(s): Belema; Makonen (North Haven, CT), Nguyen; Van N. (Middletown, CT)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:14/030,199
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Bristol-myers SquibbDAKLINZAdaclatasvir dihydrochlorideTABLET;ORAL206843-001Jul 24, 2015RXYesNo► Subscribe► SubscribeMETHOD OF INHIBITING HEPATITIS C VIRUS► Subscribe
Bristol-myers SquibbDAKLINZAdaclatasvir dihydrochlorideTABLET;ORAL206843-001Jul 24, 2015RXYesNo► Subscribe► SubscribeMETHOD OF INHIBITING HEPATITIS C VIRUS WITH DAKLINZA AND AT LEAST ONE ADDITIONAL COMPOUND HAVING ANTI-HCV ACTIVITY► Subscribe
Bristol-myers SquibbDAKLINZAdaclatasvir dihydrochlorideTABLET;ORAL206843-002Jul 24, 2015RXYesYes► Subscribe► SubscribeMETHOD OF INHIBITING HEPATITIS C VIRUS► Subscribe
Bristol-myers SquibbDAKLINZAdaclatasvir dihydrochlorideTABLET;ORAL206843-002Jul 24, 2015RXYesYes► Subscribe► SubscribeMETHOD OF INHIBITING HEPATITIS C VIRUS WITH DAKLINZA AND AT LEAST ONE ADDITIONAL COMPOUND HAVING ANTI-HCV ACTIVITY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,900,566

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,421,192Hepatitis C virus inhibitors► Subscribe
8,303,944Hepatitis C virus inhibitors► Subscribe
9,758,487Hepatitis C virus inhibitors► Subscribe
9,227,961Hepatitis C virus inhibitors► Subscribe
8,642,025Hepatitis C virus inhibitors► Subscribe
8,846,023Hepatitis C virus inhibitors► Subscribe
8,574,563Hepatitis C virus inhibitors► Subscribe
8,329,159Hepatitis C virus inhibitors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,900,566

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
TaiwanI432426► Subscribe
Taiwan200813029► Subscribe
TaiwanI400072► Subscribe
Taiwan200934486► Subscribe
Slovenia2784075► Subscribe
Slovenia2049522► Subscribe
Portugal2049522► Subscribe
Poland2784075► Subscribe
Peru05422008► Subscribe
New Zealand574805► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Cantor Fitzgerald
Healthtrust
Medtronic
Novartis
Dow
McKinsey
Teva
McKesson
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot